Source comparison
Comparative Analysis: Hexarelin vs Other Growth Hormone Secretagogues
Hexarelin occupies a distinct position within the family of growth hormone-releasing peptides due to its receptor binding affinity and GH pulse amplitude. When compared to GHRP-2, GHRP-6, ipamorelin, and CJC-1295, hexarelin consistently produces the highest pe
This comparison does not assign a generated winner or score.
- Hexarelin occupies a distinct position within the family of growth hormone-releasing peptides due to its receptor binding affinity and GH pulse amplitude. When compared to GHRP-2, GHRP-6, ipamorelin, and CJC-1295, hexarelin consistently produces the highest peak GH levels but also exhibits the most pronounced desensitization over time. Understanding these trade-offs is critical for designing muscle growth research protocols that balance acute GH response with long-term sustainability.
- Hexarelin
- 8–15×
- 12–16 weeks (continuous use)
- Moderate (appetite stimulation, gastric motility)
- 50–200 mcg per dose
- High affinity GHS-R1a agonist
- Highest acute GH response; requires cycling to preserve efficacy. Best for short-term intensive protocols or pulsed designs.
- GHRP-6
- 5–8×
- Minimal (>24 weeks)
- High (significant appetite increase)
- 100–300 mcg per dose
- Moderate GHS-R1a affinity
- Sustained response over time; pronounced hunger side effect limits use in calorie-controlled studies.
- GHRP-2
- 6–10×
- Mild (16–20 weeks)
- Low
- Balanced profile. Good pulse amplitude without severe appetite effects or rapid desensitization.
- Ipamorelin
- 3–5×
- Very low
- 200–500 mcg per dose
- Selective GHS-R1a, low off-target binding
- Gentlest GH release; ideal for protocols prioritizing receptor preservation and minimal side effects, but lower peak response.
- CJC-1295 (No DAC)
- 2–4× (synergistic with GHRPs)
- Minimal
- None (GHRH analog, not ghrelin-mimetic)
- 100–200 mcg per dose
- GHRH receptor agonist
- Does not compete with GHS-R1a; stacks with hexarelin to amplify and prolong GH pulse duration.
- MK-677 (Ibutamoren)
- 2–4×
- Moderate (gradual attenuation after 6–12 months)
- Moderate
- 10–25 mg oral daily
- Oral GHS-R1a agonist
- Non-peptide oral alternative; convenient but lower peak GH and slower IGF-1 kinetics than injectable hexarelin.
- Hexarelin's superior GH pulse amplitude makes it the preferred choice for short-duration, high-intensity muscle growth studies where maximal anabolic signaling is prioritized. However, protocols extending beyond 12–16 weeks should incorporate cycling intervals or transition to ipamorelin or GHRP-2 to maintain receptor sensitivity. Combination protocols using hexarelin with CJC1295 Ipamorelin 5MG 5MG capitalize on synergistic mechanisms. CJC-1295 amplifies the GH pulse initiated by hexarelin by preventing somatostatin-mediated suppression, producing GH elevations 40–60% higher than either peptide alone.